Skip to Content

NRG-BN007: A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma (Location: Pierre)


temporarily closed to patient enrollment as of 25Apr2022

Clinical Trial Details >>

Principal Investigator(s)
Benjamin Solomon, MD

Clinical Trial Categories

  • Brain Cancer
Medical Oncology Research Coordinators at 605-322-3295


  • Avera Cancer Institute at Pierre
    801 E. Sioux Ave.
    Pierre, SD 57501
    Main: 605-224-3370
    Fax: 605-224-3296

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.